Skip to main content
. Author manuscript; available in PMC: 2020 Sep 23.
Published in final edited form as: Ann Surg. 2018 Apr;267(4):692–699. doi: 10.1097/SLA.0000000000002164

Table 3.

A comparison of end-of-life outcomes based upon treatment for malignancy-associated bowel obstruction among decedents with stage IV ovarian or pancreatic cancer using multivariate competing risks regressiona (N = 3,279)

Treatment for MBO
Medical Management % % Surgery SDHRb 95% CI % VGT SDHRb 95% CI
Enrolled in hospice 64.3 63.0 0.84* 0.76-0.92 76.4 1.65* 1.42-1.91
ICU care in last days of life 18.2 24.4 1.38* 1.17-1.64 12.8 0.69* 0.52-0.93
Death in an acute care hospital 27.8 25.3 0.91 0.78-1.06 13.8 0.47* 0.36-0.63
*

p < 0.05

a

Regression models are adjusted for age group, sex, race, Charlson Comorbidity Index, primary cancer site, hospital size, teaching status, and region

b

Reference group included patients treated with medical management during all MBO admissions

Abbreviations: CI, confidence interval; ICU, intensive care unit; MBO, malignancy-associated bowel obstruction; SDHR, subdistribution hazards ratio; VGT, venting gastrostomy tube